{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:04:40Z","timestamp":1776805480869,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jphs.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:45:47Z","timestamp":1742024747000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"158","author":[{"given":"Shuyue","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongtian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jphs.2025.03.006_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jphs.2025.03.006_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.kint.2020.06.017","article-title":"The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds","volume":"98","author":"Jonsson","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.jphs.2025.03.006_bib3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.kint.2021.03.041","article-title":"The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis","volume":"100","author":"Lambourg","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.jphs.2025.03.006_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/med.21527","article-title":"Erythropoiesis and chronic kidney disease-related anemia: from physiology to new therapeutic advancements","volume":"39","author":"Cernaro","year":"2019","journal-title":"Med Res Rev"},{"issue":"16","key":"10.1016\/j.jphs.2025.03.006_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","article-title":"Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors","volume":"82","author":"Locatelli","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jphs.2025.03.006_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108272","article-title":"Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors","volume":"239","author":"Sugahara","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2025.03.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2019.109869","article-title":"Prevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)","volume":"128","author":"Pu","year":"2020","journal-title":"J Psychosom Res"},{"issue":"6","key":"10.1016\/j.jphs.2025.03.006_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","article-title":"Recent and emerging therapies for iron deficiency in anemia of CKD: a review","volume":"79","author":"Bazeley","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.jphs.2025.03.006_bib9","article-title":"Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease","volume":"8","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.jphs.2025.03.006_bib10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jphs.2025.03.006_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.ajkd.2018.12.047","article-title":"Vision impairment in CKD patients: epidemiology, mechanisms, differential diagnoses, and prevention","volume":"73","author":"Nusinovici","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jphs.2025.03.006_bib12","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Chung","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jphs.2025.03.006_bib13","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3389\/fphar.2018.01498","article-title":"Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective","volume":"9","author":"Aapro","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2025.03.006_bib14","article-title":"Role of erythropoiesis-stimulating agents in cardiovascular protection in CKD patients: reappraisal of their impact and mechanisms","author":"Miura","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jphs.2025.03.006_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/TCRM.S293879","article-title":"Profile of daprodustat in the treatment of renal anemia due to chronic kidney disease","volume":"17","author":"Ishii","year":"2021","journal-title":"Therapeut Clin Risk Manag"},{"issue":"7-8","key":"10.1016\/j.jphs.2025.03.006_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1345\/aph.1A416","article-title":"Darbepoetin alfa: a novel erythropoiesis-stimulating protein","volume":"36","author":"Joy","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.jphs.2025.03.006_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.34067\/KID.0001442020","article-title":"Management of anemia in nondialysis chronic kidney disease: current recommendations, real-world practice, and patient perspectives","volume":"1","author":"Guedes","year":"2020","journal-title":"Kidney"},{"issue":"2","key":"10.1016\/j.jphs.2025.03.006_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jphs.2020.02.010","article-title":"Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice","volume":"143","author":"Nishide","year":"2020","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.jphs.2025.03.006_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jphs.2020.09.004","article-title":"Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice","volume":"144","author":"Li","year":"2020","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2025.03.006_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.jphs.2025.03.006_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/jgs.17565","article-title":"Unexplained anemia of aging: etiology, health consequences, and diagnostic criteria","volume":"70","author":"Guralnik","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jphs.2025.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.jphs.2025.03.006_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"10.1016\/j.jphs.2025.03.006_bib24","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jphs.2025.03.006_bib25","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis. Article","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jphs.2025.03.006_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial. Journal article; clinical trial protocol","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.jphs.2025.03.006_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3904\/kjim.2022.318","article-title":"The role of roxadustat in chronic kidney disease patients complicated with anemia","volume":"38","author":"Liu","year":"2023","journal-title":"Kor J Intern Med"},{"issue":"9","key":"10.1016\/j.jphs.2025.03.006_bib28","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cells9092039","article-title":"Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review","volume":"9","author":"Hamza","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jphs.2025.03.006_bib29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.kint.2020.04.040","article-title":"Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo","volume":"98","author":"Broeker","year":"2020","journal-title":"Kidney Int"},{"issue":"13-15","key":"10.1016\/j.jphs.2025.03.006_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1089\/ars.2022.0004","article-title":"Oxygen sensing in innate immune cells: how inflammation broadens classical hypoxia-inducible factor regulation in myeloid cells","volume":"37","author":"Winning","year":"2022","journal-title":"Antioxidants Redox Signal"},{"issue":"11","key":"10.1016\/j.jphs.2025.03.006_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.63.11.7","article-title":"Hypoxia-inducible factor-1\u03b1 in rods is neuroprotective following retinal detachment","volume":"63","author":"Ross","year":"2022","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jphs.2025.03.006_bib32","article-title":"Efficacy and safety of daprodustat Vs rhEPO for anemia in patients with chronic kidney disease: a meta-analysis and trial sequential analysis","volume":"13","author":"Fu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jphs.2025.03.006_bib33","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.jphs.2025.03.006_bib34","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional Epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jphs.2025.03.006_bib35","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/0886022X.2020.1811121","article-title":"Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients","volume":"42","author":"Wang","year":"2020","journal-title":"Ren Fail"},{"issue":"6","key":"10.1016\/j.jphs.2025.03.006_bib36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1744-9987.13686","article-title":"Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients","volume":"25","author":"Kanai","year":"2021","journal-title":"Ther Apher Dial"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T13:26:00Z","timestamp":1742995560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861325000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1347861325000271"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.03.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}